1. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil 
Ivan S. Moiseev, Olga V. Pirogova, Alexandr L. Alyanski, Elena V. Babenko, Tatyana L. Gindina, Elena I. Darskaya, Olga A. Slesarchuk, Sergey N. Bondarenko, Boris V. Afanasyev 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 6, Pages (June 2016)
DOI: /j.bbmt
Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Cumulative incidence of aGVHD and cGVHD, NRM, survival, and GRFS. (A) Incidence of aGVHD grades II to IV in the PTCy group (19%; 95% CI, 13% to 30%) versus the ATG group (45%; 95% CI, 36% to 54%), P =  (B) Incidence of aGVHD grades III to IV in the PTCy group (4%; 95% CI, 1% to 11%) versus the ATG group (27%; 95% CI, 20% to 36%), P <  (C) Incidence of moderate and severe cGVHD in the PTCy group (16%; 95% CI, 9% to 29%) versus the ATG group (65%; 95% CI, 55% to 77%), P <  (D) NRM in the PTCy (16%; 95% CI, 9% to 27%) versus the ATG group (36%; 95% CI, 29% to 46%), P = .005. (E) OS in the PTCy group (69%; 95% CI, 56% to 79%) versus the ATG group (40%; 95% CI, 32% to 49%), P =  (F) GRFS in the PTCy group (52%; 95% CI, 40% to 63%) versus the ATG group (12%; 95% CI, 7% to 18%), P < .0001.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Multivariate analysis plots for aGVHD, cGVHD, and EFS. Age indicates age/10; CD34+ >3.0 × 106/kg, concentration of CD34+ cells in the graft; Disease status, CR1, CR2, ≥CR2; HCT-CI, hematopoietic cell transplantation–specific comorbidity index.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions